Mayo Clinic Platform

AccurKardia is an innovative company specializing in ECG-led diagnostics software. It transforms ECG data into a powerful tool to improve patient outcomes globally, with initial applications in cardiology. The company offers AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for automated, near real-time ECG interpretation. Its AI-driven hyperkalemia detection solution, AK+ Guard™, received FDA Breakthrough Device Designation.

Founded in 2020, Saigeware is a healthcare technology company based in Karnataka, India. It specializes in developing AI-based platforms to support evidence-based medicine, focusing on cardiac and pulmonary practices. The company offers telemedicine services, drug discovery solutions, and personal wellness applications, empowering doctors and patients with actionable health insights.

Founded in 2019, SOAP Health improves clinical decision-making by capturing and analyzing patient data before appointments. Its platform offers augmented intelligence for physicians, graphical risk representation, and actionable insights to enhance patient care and doctor productivity.

Biotia, Inc. is a health technology company based in New York, founded in 2016. It specializes in developing software and laboratory technologies that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery and management. By providing tailored microbial surveillance, Biotia's innovative solutions enable clinicians and researchers to identify and mitigate pathogens effectively, thereby reducing hospital-acquired infections and improving patient outcomes. The company's technology empowers healthcare professionals to guide treatment decisions proactively, ultimately aiming to prevent illnesses before they occur.

Dynocardia is a biomedical device company developing wearable, non-invasive blood pressure monitoring technology. Its ViTrack wrist-wearable device provides direct, beat-by-beat measurement of blood pressure and tracks heart rate, respiration, and rhythm with accuracy comparable to intra-arterial lines. The platform uses a wearable optomechanical sensor to enable continuous, mobile monitoring of cardiovascular parameters. Founded in 2018, the company is headquartered in Massachusetts and focuses on meeting critical clinical needs with portable monitoring solutions.

Delfina is a data-driven prenatal care platform that personalizes pregnancy care to improve safety for mothers and babies. It uses a data-powered approach to uncover insights in prenatal care and to optimize interventional workflows through machine learning models. The platform creates individualized pregnancy care plans based on patient risk assessed from multiple metrics and supports early intervention, helping providers deliver equitable, cost-effective care. By integrating data across clinical, demographic, and monitoring inputs, Delfina aims to enhance decision-making, streamline workflows, and improve outcomes throughout pregnancy.

ImpriMed, Inc. is a biotechnology company focused on providing personalized drug response prediction services for veterinary oncology. Established in 2017 and headquartered in Palo Alto, California, with an additional office in Seoul, South Korea, the company specializes in analyzing the drug responses of live cancer cells from pets, particularly in cases of lymphoma. By collecting genetic and cellular information from these cancer cells, ImpriMed develops precision medicine techniques that assist veterinary oncologists in selecting the most effective anticancer treatments for individual pets. This patient-derived database not only enhances treatment decisions for animals but also has the potential to translate insights into human oncology, ultimately aiding in the development of tailored cancer therapies for humans.